Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b

被引:29
|
作者
Gitlin, G [1 ]
Tsarbopoulos, A [1 ]
Patel, ST [1 ]
Sydor, W [1 ]
Pramanik, BN [1 ]
Jacobs, S [1 ]
Westreich, L [1 ]
Mittelman, S [1 ]
Bausch, JN [1 ]
机构
[1] SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033
关键词
protein mapping; mass spectrometry; methionine oxidation;
D O I
10.1023/A:1016059902645
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To isolate and characterize a monomethioninesulfoxide variant of the commercially available therapeutic protein interferon alpha-2b. Methods. The methionine (Met)-oxidized variant was isolated by reverse-phase high performance liquid chromatography and characterized by SDS-PAGE, peptide mapping and mass spectrometric analysis of the trypsin/V8-generated peptide fragments. The biological and immunological activities of the isolated variant were also evaluated. Results. The rHuIFN alpha-2b variant was found to contain a Met sulfoxide residue at position ill of the rHuIFN alpha-2b molecule. The far-UV CD spectra showed a slight loss of alpha-helical content and an increase in the beta-sheet contribution. The CD spectra indicate that both chromatographic conditions and Met oxidation contribute to the observed secondary structure changes. Both interferon alpha-2b main component and its methionine-oxidized variant showed different reactivity to monoclonal antibodies employed in immunoassays for the protein. Conclusions. A monomethioninesulfoxide rHuIFN alpha-2b variant was found to be present in the rHuIFN alpha-2b bulk drug substance in solution. The Met(111) residue was identified as Met sulfoxide by comparative tryptic/V8 mapping and mass spectrometric analysis. Nevertheless, the oxidation of the Met(111) residue did not seem to have a detectable effect on the biological activity of the molecule.
引用
收藏
页码:762 / 769
页数:8
相关论文
共 50 条
  • [31] TREATMENT OF CHRONIC HEPATITIS-B WITH RECOMBINANT ALPHA-2B INTERFERON
    MULLER, R
    BAUMGARTEN, R
    MARKUS, R
    SCHULZ, M
    WITTENBERG, H
    HINTSCHEKILGER, B
    FENGLER, JD
    VONWUSSOW, P
    MEISEL, H
    KLEIN, H
    MALMUS, K
    SCHMIDT, FW
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1990, 115 (11) : 403 - 407
  • [32] Acute hepatitis-C - Treatment with interferon alpha-2b
    Thimme, R
    Blum, HE
    INTERNIST, 2002, 43 (09): : 1148 - 1150
  • [33] ROLE OF INTERFERON ALPHA-2B IN HYPERTROPHIC SCARRING INVITRO AND INVIVO
    TREDGET, E
    SHANKOWSKY, H
    SHEN, Y
    NEDELEC, B
    DODD, C
    SCOTT, P
    GHAHARY, A
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 139 - 139
  • [34] Human Interferon Alpha-2b: A Therapeutic Protein for Cancer Treatment
    Ningrum, Ratih Asmana
    SCIENTIFICA, 2014, 2014
  • [35] Interferon alpha-2b recombinant in multiple sclerosis: Preliminary report
    Cabrera, JA
    Lopez-Saura, P
    Santana, E
    Casanova, M
    NEUROLOGY, 1999, 52 (06) : A291 - A291
  • [36] Successful treatment of osteoporosis in systemic: Mastocytosis with interferon alpha-2b
    Weide, R
    Ehlenz, K
    Lorenz, W
    Walthers, E
    Klausmann, M
    Pfluger, KH
    ANNALS OF HEMATOLOGY, 1996, 72 (01) : 41 - 43
  • [37] Choroidal changes after intravitreal injection of interferon alpha-2b
    Eghtedari, Masoomeh
    Afarid, Mehrdad
    Ashraf, Hossein
    Maalhagh, Mehrnoosh
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2019, 244 (14) : 1144 - 1148
  • [38] Alopecia areata during interferon alpha-2b/ribavirin therapy
    Agesta, N
    Zabala, R
    Díaz-Pérez, JL
    DERMATOLOGY, 2002, 205 (03) : 300 - 301
  • [39] Recombinant interferon alpha-2b in the management of malignant pleural effusions
    Wilkins, HE
    Connolly, MM
    Grays, P
    Marquez, G
    Nelson, D
    CHEST, 1997, 111 (06) : 1597 - 1599
  • [40] RECOMBINANT ALPHA-2B INTERFERON IN REFRACTORY IDIOPATHIC IMMUNE THROMBOCYTOPENIA
    IANNACCARO, P
    MOLICA, S
    SANTORO, R
    MULEO, G
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1992, 48 (05) : 271 - 271